Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic modification of the marine-derived yeast Yarrowia lipolytica with high-protein content using a GPI-anchor-fusion expression system.

Biotechnology progress·2009
Same author

Regulation of the Edwardsiella tarda hemolysin gene and luxS by EthR.

Journal of microbiology and biotechnology·2009
Same author

EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.

Cellular & molecular immunology·2009
Same author

[Combination of volar buttress plate with external fixator for the distal radial fractures of type C3 caused by high-energy injuries].

Zhongguo gu shang = China journal of orthopaedics and traumatology·2009
Same author

Environmental regulation of floral anthocyanin synthesis in Ipomoea purpurea.

Molecular ecology·2009
Same author

PI3K integrates the effects of insulin and leptin on large-conductance Ca2+-activated K+ channels in neuropeptide Y neurons of the hypothalamic arcuate nucleus.

American journal of physiology. Endocrinology and metabolism·2009

Related Experiment Video

Updated: May 18, 2026

Isolation of Double Negative αβ T Cells from the Kidney
06:56

Isolation of Double Negative αβ T Cells from the Kidney

Published on: May 16, 2014

Double-Filtration Plasmapheresis for ABO-Incompatible Living-Donor Kidney Transplantation.

Xiaochun Zhou1,2, Youmin Yang3, Yingying Yang1

  • 1Department of Nephrology and Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu, China.

Blood Purification
|May 16, 2026
PubMed
Summary

Double filtration plasmapheresis (DFPP) significantly reduces acute rejection and patient mortality in ABO-incompatible kidney transplants (KTx) compared to plasma exchange (PE). DFPP also leads to shorter hospital stays, offering a more favorable long-term prognosis for ABO-incompatible kidney transplant recipients.

Keywords:
ABO-incompatible kidney transplantationDouble-filtration plasmapheresisIsoagglutininsKidney transplantationPlasma exchange

More Related Videos

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
09:15

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach

Published on: May 7, 2019

Related Experiment Videos

Last Updated: May 18, 2026

Isolation of Double Negative αβ T Cells from the Kidney
06:56

Isolation of Double Negative αβ T Cells from the Kidney

Published on: May 16, 2014

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
09:15

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach

Published on: May 7, 2019

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Medical Technology

Background:

  • ABO-incompatible (ABOi) kidney transplantation (KT) is a viable renal replacement therapy.
  • Effective ABO antibody clearance is crucial for successful ABOi-KT outcomes.
  • Both double filtration plasmapheresis (DFPP) and plasma exchange (PE) remove isoagglutinins, but comparative long-term data are limited.

Purpose of the Study:

  • To compare the efficacy and long-term prognosis of DFPP versus PE in patients undergoing ABOi-KT.
  • To evaluate the impact of these apheresis techniques on acute rejection, infection, graft loss, and patient survival.

Main Methods:

  • A retrospective study of 230 ABOi living donor KTs performed between September 2014 and April 2024.
  • Patients were divided into DFPP and PE groups.
  • Propensity score matching (PSM) was used to create comparable groups for analysis of outcomes including acute rejection, infection, graft loss, patient death, and isoagglutinin titers (IgG and IgM).

Main Results:

  • Post-PSM analysis included 63 patients in the DFPP group and 24 in the PE group.
  • DFPP showed significantly lower 6-month acute rejection (6.3% vs. 33.3%) and patient mortality (0% vs. 12.5%) compared to PE.
  • DFPP resulted in shorter hospital stays (22 vs. 42 days) and a significantly lower risk of AR (OR=0.142) compared to PE, despite similar isoagglutinin reduction.

Conclusions:

  • DFPP is associated with superior short-term outcomes, including reduced acute rejection and patient mortality, in ABOi-KT compared to PE.
  • DFPP offers a significant survival benefit and shorter hospitalization for ABOi-KT recipients.
  • Further research should explore the long-term graft survival differences and the impact of albumin and globulin depletion by DFPP.